A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury
Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Feb 17, 2016
Trial Information
Current as of June 14, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- This is a prospective randomized placebo controlled trial. All patients admitted to participating centers with newly diagnosed acute kidney injury (AKI) will be screened for eligibility. The diagnosis of AKI will be determined and staged according to the KIGO-AKI Guideline.11 The inclusion criteria include:
- • 1. Age ≥ 20 years old on the day of admission
- • 2. AKI develops during admission, as defined with KDIGO-AKI Guideline,11 namely, elevation of serum creatinine above 0.3mg/dL within two days, above 1.5times baseline.
- Patients with the following conditions will be excluded:
- • 1. Baseline estimated glomerular filtration rates (eGFR) less than 30ml/min/1.73m2 or greater than 90ml/min/1.73m2 according to MDRD equation.
- • 2. Acute kidney injury diagnosed in the indexed admission (according to baseline creatinine)
- • 3. Ileus or under fasting status
- • 4. Previous gastrointestinal operation.
- • 5. Chronic constipation, as defined with bowel movement less than three times a day. If usage of oral laxatives can achieve bowel movement of more than 3 times a day, this patient will not be excluded.
- • 6. Patients had ever undergone any modality of renal replacement therapy (RRT)
- • 7. Patients with major hemorrhage, as defined with requirement of blood transfusion during index admission.
- • 8. Patients with a biopsy proved or clinically diagnosed liver cirrhosis, Child classification B or C.
- • 9. Patients with a congestive heart failure of NYHA Class III or IV, or requirement of inotropic agents.
- • 10. Patients with a chronic lung disease requiring non-invasive or invasive positive pressure ventilation.
- • 11. Solid organ or hematological transplantation donors.
- • 12. Patients who had been diagnosed as AKI in the index hospitalization, as defined with KDIGO 2012 criteria.
- • 13. Patients with oliguric acute kidney injury, as defined with less than 500cc/day.
- • 14. Evidence of obstructive acute kidney injury under kidney echosonography.
About National Taiwan University Hospital
National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Douliou, , Taiwan
Patients applied
Trial Officials
YU-SHENG WU
Principal Investigator
National Taiwan University Hospital
Tao-Min Huang
Principal Investigator
National Taiwan University Hospital, Yun-Lin Branch
Wei-Shun Yang
Principal Investigator
National Taiwan University Hospital Hsin-Chu Branch
JUI-HSIANG LIN
Principal Investigator
Taoyuan General Hospital
Ya-Fei Yang
Principal Investigator
China Medical University Hospital
Chan-Yu Lin
Principal Investigator
Chang Gung Memorial Hospital
Heng-Chih Pan
Principal Investigator
Chang Gung Memorial Hospital
Chih-Chin Kao
Principal Investigator
Taipei Medical University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials